Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cell death : An anti-rejection drug for the treatment of Huntington’s disease

07.02.2006


At the Institut Curie, CNRS and Inserm researchers have shown that Huntington’s disease may be treated using the drug FK506, which is also used clinically to prevent graft rejection. Like Alzheimer’s and Parkinson’s, Huntington’s disease is characterized by the abnormal death of neurons.



The Institut Curie researchers have discovered that FK506 blocks the toxicity of the protein huntingtin, which causes the death of certain neurons leading to disease onset. FK506 is already used in a clinical setting and so is a candidate for fast-track development as a treatment for Huntington’s disease.

This study was published in the February 1, 2006 issue of The Journal of Neuroscience.


Huntington’s disease is a genetic disorder which affects approximately 6 000 people in France and is of concern to over 12 000 carriers of the mutated gene as yet untouched by clinical signs. It is characterized by uncontrolled movements, personality changes, dementia and death 10 to 20 years after onset of the first symptoms (see "Additional information").

Huntington’s disease results from changes in the IT15 gene, which encodes a protein, huntingtin, whose function is incompletely elucidated. Normal huntingtin contains repeats of the amino acid glutamine, but mutant huntingtin contains more than 35 to 40 glutamines and induces the disease. Symptoms occur earlier as the number of repeats increases.

This abnormal expansion of the polyglutamine tract in huntingtin results in structural changes, and the mutant huntingtin accumulates in neurons thereby causing their dysfunction and ultimately their death.

The same type of mutation causes other neurodegenerative diseases, each involving different regions of the brain. In Huntington’s disease, degeneration occurs in the neurons of the striatum, which are involved in the control of movement.

Raúl Pardo and Emilie Colin at the Institut Curie are studying the mechanisms that lead to neuron death in Huntington’s disease, under the direction of Frédéric Saudou and Sandrine Humbert(1).

They have now shown that calcineurin, a protein abundant in the brain, chemically alters mutant huntingtin, which becomes more toxic for neurons.

They have also discovered that by inhibiting calcineurin, FK506 “corrects” this chemical alteration in mutant huntingtin both in cultured neurons and in an animal model of the disease. FK506 even prevents the death of the striatal neurons. So, FK506 negates the harmful effects of mutant huntingtin in neurons.

FK506 is already used therapeutically to prevent graft rejection, and so may be a candidate for fast-track development as a treatment for Huntington’s disease.

Catherine Goupillon | alfa
Further information:
http://www.jneurosci.org/
http://www.curie.fr

More articles from Life Sciences:

nachricht Immune Defense Without Collateral Damage
23.01.2017 | Universität Basel

nachricht The interactome of infected neural cells reveals new therapeutic targets for Zika
23.01.2017 | D'Or Institute for Research and Education

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>